Trial Profile
Observational Study of Correction of Anaemia With Darbepoetin Alfa at Monthly Dose Frequency in EU and Australian Patients With Chronic Kidney Disease Not on Dialysis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Darbepoetin alfa (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Acronyms ADAPTATION
- Sponsors Amgen
- 28 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 18 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Jul 2014 New trial record